AU2014354821A1 — Combination therapy comprising an inhibitor of JAK, CDK and PIM
Assigned to Novartis AG · Expires 2016-05-26 · 10y expired
What this patent protects
The present invention relates to a pharmaceutical combination which comprises (a) a JAK inhibitor compound, (b) a CDK inhibitor, and (c) a PIM kinase inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use,…
USPTO Abstract
The present invention relates to a pharmaceutical combination which comprises (a) a JAK inhibitor compound, (b) a CDK inhibitor, and (c) a PIM kinase inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of a myeloid neoplasm or leukemia; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of myeloid neoplasm or leukemia; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a mammal, especially a human.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.